These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 34733240)
1. Oestradiol Contributes to Differential Antitumour Effects of Adjuvant Zoledronic Acid Observed Between Pre- and Post-Menopausal Women. Canuas-Landero VG; George CN; Lefley DV; Corness H; Muthana M; Wilson C; Ottewell PD Front Endocrinol (Lausanne); 2021; 12():749428. PubMed ID: 34733240 [TBL] [Abstract][Full Text] [Related]
2. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891 [TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Ottewell PD; Wang N; Brown HK; Reeves KJ; Fowles CA; Croucher PI; Eaton CL; Holen I Clin Cancer Res; 2014 Jun; 20(11):2922-32. PubMed ID: 24687923 [TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548 [TBL] [Abstract][Full Text] [Related]
5. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Haider MT; Holen I; Dear TN; Hunter K; Brown HK Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713 [TBL] [Abstract][Full Text] [Related]
6. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study. Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100 [TBL] [Abstract][Full Text] [Related]
7. Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. George CN; Canuas-Landero V; Theodoulou E; Muthana M; Wilson C; Ottewell P J Bone Oncol; 2020 Dec; 25():100317. PubMed ID: 32995253 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. Ottewell PD; Mönkkönen H; Jones M; Lefley DV; Coleman RE; Holen I J Natl Cancer Inst; 2008 Aug; 100(16):1167-78. PubMed ID: 18695136 [TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467 [TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701 [TBL] [Abstract][Full Text] [Related]
11. Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models. Rogers TL; Wind N; Hughes R; Nutter F; Brown HK; Vasiliadou I; Ottewell PD; Holen I Cell Oncol (Dordr); 2013 Dec; 36(6):505-14. PubMed ID: 24177992 [TBL] [Abstract][Full Text] [Related]
12. Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study. Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Kann P Breast Cancer Res Treat; 2014 Apr; 144(2):343-51. PubMed ID: 24519387 [TBL] [Abstract][Full Text] [Related]
13. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079 [TBL] [Abstract][Full Text] [Related]
14. Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer - An AZURE (BIG 01/04) sub-study. Wilson C; Hinsley S; Marshall H; Cameron D; Bell R; Dodwell D; Coleman RE J Bone Oncol; 2017 Nov; 9():48-54. PubMed ID: 29234591 [TBL] [Abstract][Full Text] [Related]
15. Smart Delivery of Biomolecules Interfering with Peri-Implant Repair in Osteoporotic Rats. Paludetto LV; Monteiro NG; Breseghello I; de Souza Batista FR; Antoniali C; Lisboa-Filho PN; Okamoto R Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201648 [TBL] [Abstract][Full Text] [Related]
16. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial. Kyvernitakis I; Kann PH; Thomasius F; Hars O; Hadji P Bone; 2018 Sep; 114():109-115. PubMed ID: 29908297 [TBL] [Abstract][Full Text] [Related]
17. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Coleman RE; Collinson M; Gregory W; Marshall H; Bell R; Dodwell D; Keane M; Gil M; Barrett-Lee P; Ritchie D; Bowman A; Liversedge V; De Boer RH; Passos-Coelho JL; O'Reilly S; Bertelli G; Joffe J; Brown JE; Wilson C; Tercero JC; Jean-Mairet J; Gomis R; Cameron D J Bone Oncol; 2018 Nov; 13():123-135. PubMed ID: 30591866 [TBL] [Abstract][Full Text] [Related]
18. Genetically-achieved disturbances to the expression levels of TNFSF11 receptors modulate the effects of zoledronic acid on growing mouse skeletons. Vargas-Franco JW; Castaneda B; Gama A; Mueller CG; Heymann D; Rédini F; Lézot F Biochem Pharmacol; 2019 Oct; 168():133-148. PubMed ID: 31260659 [TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid enhances bone-implant osseointegration more than alendronate and strontium ranelate in ovariectomized rats. Chen B; Li Y; Yang X; Xu H; Xie D Osteoporos Int; 2013 Jul; 24(7):2115-21. PubMed ID: 23389695 [TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. Hung TT; Chan J; Russell PJ; Power CA PLoS One; 2011; 6(5):e19389. PubMed ID: 21603655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]